Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

• Published in: Scientific reports Vol. 11; no. 1; p. 16122
• Main Authors: Shen, Chia-I, Chao, Heng-Sheng, Shiao, Tsu-Hui, Chiang, Chi-Lu, Huang, Hsu-Ching, Luo, Yung-Hung, Chiu, Chao-Hua, Chen, Yuh-Min
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 09.08.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4028; 692/4028/67/1059; 692/4028/67/1612; 692/4028/67/395; 692/4028/67/580; Chemotherapy; Epidermal growth factor receptors; Humanities and Social Sciences; Immunotherapy; Lung cancer; multidisciplinary; Mutants; Mutation; Non-small cell lung carcinoma; Patients; Science; Science (multidisciplinary); Small cell lung carcinoma
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-95628-w

Whether ICIs combined with chemotherapy can improve outcomes in EGFR -mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated with ICIs or ICIs combined chemotherapy (ICI + C). Total 30 patients were included. The ORR were 9.1% and 25.0% for the ICI and ICI + C groups. The ICI + C group showed the trend of longer progression-free survival and overall survival periods. Patients without the T790M mutation had a significantly longer PFS than did those without this mutation (4.23 [95% CI: 2.75–5.72] vs. 1.70 [95% CI: 0.00–3.51] months, HR:4.45, p  = 0.019). ICIs combined with chemotherapy tended to be more effective than ICIs alone in pretreated EGFR -mutant NSCLC. The T790M mutation may be a potential biomarker.